SEC Form 4 · accession 0001209191-18-005357

AGIOS PHARMACEUTICALS, INC. · AGIO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

David P Schenkein

Officer — Chief Executive Officer · Director

Period of report

Jan 23, 2018

Accepted (ET)

Jan 25, 2018 · 4:03 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001439222

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common stock	Jan 23, 2018	M	32,875	$0.3025	A	32,875	D
Common stock^F3	Jan 23, 2018	S	32,875	$80.01	D	0	D
Common stock	Jan 24, 2018	M	13,533	$0.3025	A	13,533	D
Common stock^F4	Jan 24, 2018	S	13,533	$80.01	D	0	D
Common stock^F5	holding	—	—		—	271,772	I	See footnote
Common stock^F6	holding	—	—		—	79,082	I	See footnote

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock option (right to buy)^F7	$0.3025	Jan 23, 2018	M	32,875	D	—	Aug 12, 2019	Common stock	32,875	5,962	D
Stock option (right to buy)^F8	$0.3025	Jan 24, 2018	M	13,533	D	—	Aug 12, 2019	Common stock	13,533	141,159	D

Explanation of responses

F1This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F3The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $80.00 to $80.10. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F4The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $80.00 to $80.07. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F5Shares held by David P. Schenkein 2004 Revocable Trust, of which the reporting person is trustee and beneficiary.
F6Shares held by Amy P. Schenkein 2004 Revocable Trust, of which the reporting person's spouse is trustee and beneficiary.
F7This option was granted on August 13, 2009. The shares underlying this option vest as to 25% of the shares on August 1, 2010, with the remaining 75% vesting in 36 equal monthly installments thereafter.
F8This option was granted on August 13, 2009. The option vested as to 50% of the underlying shares upon the achievement of a performance milestone, as determined by the issuer's Board of Directors on June 3, 2010, and as to the remaining 50% of the underlying shares in equal monthly installments through June 3, 2013.